On 8 February 2026, Relfydess launched in the UAE, the first ready-to-use liquid wrinkle relaxer to be registered in the country. Relfydess is Galderma's new generation neuromodulator, and the launch brought together aesthetic physicians and industry leaders to mark a genuine first for the UAE market.
The change looks small on paper, a different format in the vial, but it affects how the treatment is prepared and delivered. Here is what Relfydess is, what the evidence behind it shows, and why its arrival in the UAE matters.
Relfydess is a neuromodulator from Galderma, a long-established name in aesthetic injectables. Its active ingredient is RelabotulinumtoxinA, a purified form of botulinum toxin type A that is free from the complexing proteins found in older preparations. It is made using Galderma's PEARL technology, which delivers the active in a stable, ready-to-use liquid.
The way it works is familiar. Relfydess relaxes the specific muscles behind expression lines, so the skin above them softens and looks smoother. What is new is the form it comes in, and the consistency that form makes possible.
For two decades, wrinkle relaxers have come as a freeze dried powder that has to be reconstituted by hand before every treatment. The practitioner draws up saline, mixes the vial, and prepares the dose. It works, but each manual step is a small chance for variation from one preparation to the next.
Relfydess removes that step. It is supplied ready to use at 100 units per millilitre, with no reconstitution required, and is drawn straight from the vial. Taking the mixing out of the workflow leaves one less variable between the treatment plan and the result, which supports more consistent dosing session to session.
Relfydess comes in a single 1.5 millilitre vial, intended for one patient in one treatment session. Any product left over is discarded rather than carried across to someone else. The principle is simple, and the benefit is practical: it supports accuracy and removes the shared-vial handling that some older workflows relied on.
Two numbers stand out here, both from Galderma's registration data.
Relfydess has shown onset within one day of injection. Its effect has been demonstrated for six months, where many established options are revisited closer to three or four. And it is well evidenced: three Phase 3 trials, more than 800 patients, before it reached the market.
Quick to take effect, slow to wear off. That is what earns it the new generation label.
Relfydess is used to soften two of the most common areas of facial expression lines: frown lines between the brows (glabellar lines) and the lines around the eyes known as crow's feet (lateral canthal lines), alone or together. Like every treatment in this category, it is a medical procedure that should only be given by trained, qualified practitioners. The right candidate and the right hands matter more than any single product feature.
Relfydess is approved for use in the UAE by the Emirates Drug Establishment (EDE), under registration number 72881-1572-189267. It is for medical use only.
What makes that worth noting is the timing. Relfydess is newly registered in the UAE, joining a product already approved across the European Union, the United Kingdom, and other markets worldwide. For UAE clinicians, it means working with a new generation neuromodulator early, rather than waiting years for it to arrive.
Invalid embed URL: https://www.youtube.com/watch?v=tyhPIL5q-yw
The 8 February launch was built around Galderma's PEARL technology theme, the platform behind the liquid format. It gathered aesthetic physicians and partners from across the region, framing Relfydess as a refined approach to neuromodulation.
Relfydess reaches UAE clinics through DUBIMED, the official logistics and distribution partner for the product in the country. The handling is built around a fully temperature-controlled cold chain, from a certified pharmaceutical drugstore through to delivery, with temperature data-logger cards verifying the cold chain held in transit and product authenticity stickers applied to every unit.
For a biological product like Relfydess, where stability depends on correct handling, that controlled cycle is what protects the integrity of every vial. It also means each unit reaching a UAE clinic can be verified as genuine, registered with the Emirates Drug Establishment, and handled to standard from the warehouse to the treatment room.
Explore more articles you might find interesting
